Grifols Stock

Grifols Equity

The The Equity of Grifols (GRF.MC) as of Aug 14, 2026 is 5.27 B EUR. In the previous year, The Equity was 5.88 B EUR — a change of -10.40% (lower).

Equity

5.27 BEUR

YoY

-10.40%

Last updated:

In 2026, Grifols's equity was 5.27 B EUR, a -10.40% increase from the 5.88 B EUR equity in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Grifols Stock analysis

What does Grifols do? Grifols SA is a globally operating company specialized in the manufacture and marketing of medical products and technologies. The company is headquartered in Barcelona, Spain and has been in existence for over 75 years. Grifols focuses on improving the quality of life through the production and marketing of blood products and services, diagnostics, and hospital pharmaceuticals. It has four main business areas: Bioscience, Hospital, Diagnostic, and Bio Supplies. Grifols emphasizes research and development to meet customer needs. It has introduced various products, including AlfaBIO, Vistogard, ID Core XT, NEO Blood Bank, and MIRASOL Pathogen Reduction Technology. Grifols is committed to innovation and quality, providing products and services that cater to a wide range of customers. Additionally, it is a significant employer in the biotechnology industry and contributes to economic development in different regions. Grifols is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Grifols's Equity

Grifols's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Grifols's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Grifols's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Grifols's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Grifols’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Grifols stock

The Equity of Grifols is 5.27 B EUR in 2026.

The Equity of Grifols changed from 5.88 B EUR to 5.27 B EUR, representing a -10.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Grifols since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Grifols historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Grifols

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Grifols